Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: A population-based nested casecontrol study

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1888-1894

  Weir, Matthew A ^a,b   Gomes, Tara ^c   Mamdani, Muhammad ^c,d,e,f   Juurlink, David N ^c,d,e   Hackam, Daniel G ^b,g   Mahon, Jeffrey L ^b   Jain, Arsh K ^a,b   Garg, Amit X ^a,b,c  

^a Division of Nephrology   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d Department of Medicine ^*  (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Division of Clinical Pharmacology   (Canada)

Author keywords

CKD; glyburide; hypoglycaemia; insulin; metformin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; INSULIN; METFORMIN;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; CANADA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; METFORMIN; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 79958080038     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq649     Document Type: Article

References (51)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
3. Dahl-Jorgensen K, Bjoro T, Kierulf P et al. Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 1992; 41: 920-923.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
5. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2: 1300-1304. (Pubitemid 17177864)
6. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
7. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
8. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309. (Pubitemid 23148093)
9. Cooper L. USRDS. 2001 Annual Data Report. Nephrol News Issues 2001; 1531, 34-35, 38.
10. Lok CE, Oliver MJ, Rothwell DM et al. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 2004; 19: 3098-3103. (Pubitemid 40057634)
11. Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 34i-43i.
12. Moen MF, Zhan M, Hsu VD et al. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clin J Am Soc Nephrol 2009; 1121-1127.
13. Gerich JE, Meyer C, Woerle HJ et al. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-391. (Pubitemid 32119142)
14. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17: 365-370. (Pubitemid 39422090)
15. Horton E, Johnson C, Lebovitz H. Carbohydrate metabolism in uremia. Ann Intern Med 1968; 68: 63-74.
16. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs 1981; 22: 295-320. (Pubitemid 12166002)
17. Jonsson A, Rydberg T, Ekberg G et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145. (Pubitemid 24035310)
18. Jonsson A, Rydberg T, Sterner G et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998; 53: 429-435. (Pubitemid 28154743)
19. Rydberg T, Jonsson A, Roder M et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026-1030. (Pubitemid 24268615)
20. Rydberg T, Jonsson A, Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther 1995; 20: 283-295.
21. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154.
22. Pearson JG, Antal EJ, Raehl CL et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986; 39: 318-324. (Pubitemid 16113641)
23. Brier ME, Bays H, Sloan R et al. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997; 29: 907-911. (Pubitemid 27251844)
24. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467-473. (Pubitemid 34030749)
25. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000; 35: 500-505.
26. Holstein A, Plaschke A, Hammer C et al. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003; 59: 91-97. (Pubitemid 36793719)
27. Coca SG, Krumholz HM, Garg AX et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384. (Pubitemid 44427424)
28. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 44-349.
29. Statistics Canada Census Report 2006. Statistics Canada. 2009. Statistics Canada. 5-4-2009.
30. Ontario Ministry of Finance. Ontario Population Projections (2008- 2036). page 24. Toronto, Ontario: ServiceOntario Publications, 2009;.
31. Levy AR, O'Brien BJ, Sellors C et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 67-71. (Pubitemid 37028596)
32. Jong P, Gong Y, Liu PP et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003; 108: 184-191. (Pubitemid 36871301)
33. Juurlink D, Preyra C, Croxford R et al. Canadian Institute for Health Information discharge abstract database: a validation study. Toronto: Institute for Clinical Evaluative Sciences, 2006; 3-15-0090.
34. Alter DA, Naylor CD, Austin P et al. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341: 1359-1367. (Pubitemid 29503576)
35. Levey AS, Greene T, Kusek JW et al. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11: 155A.
36. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation 2009; 38: 1228-1234.
37. Mamdani M, Sykora K, Li P et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330: 960-962. (Pubitemid 40592320)
38. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219. (Pubitemid 36143396)
39. Shorr RI, Ray WA, Daugherty JR et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-1686. (Pubitemid 27327403)
40. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999; 16: 586-590.
41. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-741. (Pubitemid 27341824)
42. Bodmer M, Meier C, Krahenbuhl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31: 2086-2091.
43. Phung OJ, Scholle JM, TalwarMet al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
44. Rabkin R, Simon NM, Steiner S et al. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970; 282: 182-187.
45. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61: 377-382.
46. Adrogue HJ. Glucose homeostasis and the kidney. Kidney Int 1992; 42: 1266-1282.
47. Castellino P, Solini A, Luzi L et al. Glucose and amino acid metabolism in chronic renal failure: effect of insulin and amino acids. Am J Physiol 1992; 262: F168-F176.
48. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347. (Pubitemid 28316896)
49. Perna AF, Fadda GZ, Zhou XJ et al. Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 1990; 259: F210-F216. (Pubitemid 20257478)
50. Census Snapshot of Canada (Age and Sex). Statistics Canada. 11-21-.2008. 5-15-2009.
51. Garg AX, Mamdani M, Juurlink DN et al. Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. J Am Soc Nephrol 2005; 16: 1433-1439 (Pubitemid 41716528)